← Leaderboards
Constantine S. Mitsiades
Dana-Farber Cancer Inst
$5,369,219
Attributed
$10,738,438
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,738,438 · 6
By mechanism
R01$7,250,508 · 4
U01$3,039,189 · 1
R21$448,741 · 1
Top collaborators
- Kenneth C Anderson10 shared
- Robert Sackstein6 shared
- Satu Mustjoki4 shared
- Nathanael Schiander Gray3 shared
- Richard Groen3 shared
- Eugen Dhimolea2 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Patrick Seale$18,417,312
- Bruce M Spiegelman$59,708,812
- Rana K. Gupta$10,967,637
- Jonathan Z Long$8,774,056
- Donald W. Kufe$50,160,456
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoMolecularIn VitroMultiple MyelomaResistanceBone MarrowGrowthTumorBaseMediatingCell ProliferationAntigen-Presenting CellsResponseNeoplastic CellInsightBiochemicalLeukemiaTherapy ResistantInvestigationPatternSignal TransductionPharmaceutical PreparationsGenetic Transcription
Grant awards (28)
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies$393,853
R01 · FY2025 · CA · contact PI
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies$9,250
R01 · FY2025 · CA · contact PI
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies$385,609
R01 · FY2024 · CA · contact PI
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis$601,611
U01 · FY2023 · CA
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies$406,038
R01 · FY2023 · CA · contact PI
Diapause-like adaptation of triple-negative breast cancer cells during chemotherapy treatment$191,280
R21 · FY2023 · CA
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis$601,611
U01 · FY2022 · CA
Diapause-like adaptation of triple-negative breast cancer cells during chemotherapy treatment$257,461
R21 · FY2022 · CA
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis$429,649
U01 · FY2021 · CA
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis$166,667
U01 · FY2021 · CA
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis$613,888
U01 · FY2020 · CA
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis$625,763
U01 · FY2019 · CA
Humanized bone marrow-like model to study patient-derived myeloma xenografts$537,912
R01 · FY2018 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2018 · CA
Humanized bone marrow-like model to study patient-derived myeloma xenografts$541,945
R01 · FY2017 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2017 · CA
Humanized bone marrow-like model to study patient-derived myeloma xenografts$563,030
R01 · FY2016 · CA · contact PI
Development and Application of Selective Covalent Cdk7 Inhibitors$501,164
R01 · FY2016 · CA
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2016 · CA
Development and Application of Selective Covalent Cdk7 Inhibitors$503,599
R01 · FY2015 · CA
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2015 · CA
Development and Application of Selective Covalent Cdk7 Inhibitors$505,961
R01 · FY2014 · CA
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2014 · CA
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$262,054
R01 · FY2013 · CA
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$278,781
R01 · FY2012 · CA
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$278,781
R01 · FY2011 · CA
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$287,403
R01 · FY2010 · CA
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$287,403
R01 · FY2009 · CA